LONDON, May 19, 2026, 15:04 (BST)
- Haleon was quoted 0.86% higher at 340.10p/340.20p on delayed Hargreaves Lansdown pricing. Hargreaves Lansdown
- The company disclosed the purchase of 8.3 million shares for cancellation under its 2026 buyback programme. Sharecast
- Wider UK stocks rose after weak labour-market data eased worries over a near-term Bank of England rate increase. Reuters
Haleon’s London-listed shares edged higher on Tuesday after the Sensodyne maker disclosed another leg of its share buyback, giving investors a fresh stock-specific cue in a firmer UK market.
Hargreaves Lansdown quoted the stock at 340.10p to sell and 340.20p to buy, up 0.86%, with prices delayed by at least 15 minutes. Haleon said on Monday it had bought 8,316,688 ordinary shares for cancellation under the buyback it announced in March. Hargreaves Lansdown
The detail matters because the buyback is doing some of the heavy lifting for the equity story while sales growth remains uneven. A buyback is when a company uses cash to repurchase its own shares; cancellation takes those shares out of circulation, reducing the share count.
The wider tape helped. The blue-chip FTSE 100, an index of large London-listed companies, was up 0.61% by 11:13 GMT after softer UK labour data cooled fears of an immediate rate hike, while the FTSE 250 rose 0.81%. Reuters
Haleon’s latest regulatory notice said the purchases were made between May 11 and May 15 across the London Stock Exchange, CBOE UK venues and Aquis. After settlement, the company said its registered share capital stood at 8,871,945,578 ordinary shares, with 8,859,815,018 carrying voting rights. Stock Titan
The company has allocated 500 million pounds to buybacks in 2026 and said at its April trading update that about 36% of that programme had been completed. Haleon says buybacks are one way it returns value to shareholders and manages capital. Haleon Corporate
That update also showed first-quarter revenue of 2.86 billion pounds and organic revenue growth of 2.2%. Organic revenue growth means sales growth adjusted to strip out factors such as currency moves and acquisitions or disposals. Haleon kept its full-year guidance for 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency. Haleon Corporate
Chief Executive Brian McNamara said the company expected “growth to accelerate across the balance of the year,” citing stronger oral health sales and a return to growth in North America. Oral Health grew 8.3% organically in the first quarter, while Respiratory Health fell 3.4% after a weak cold and flu season.
The mix is important. Haleon, spun out as a standalone consumer-health company, owns brands including Sensodyne, Panadol, Advil, Centrum, Theraflu and Voltaren, putting it in markets where brand strength can help defend pricing but where volumes can still wobble when consumers trade down or illness seasons are mild. Haleon Corporate
But the risks have not cleared. Reuters reported last month that consumer companies including Procter & Gamble and Reckitt were also dealing with higher energy and freight costs linked to the Iran conflict, while soft cold and flu demand hit Reckitt as well. Haleon finance chief Dawn Allen told analysts: “We started to see surcharges on freight,” and Quilter analyst Chris Beckett said Haleon “needs more than the toothpaste business to start performing.” Reuters
The next scheduled check is July 30, when Haleon is due to report first-half results. Investors will be looking for evidence that North America is improving, respiratory drag is fading, and the buyback is supporting the stock rather than masking weak volumes. Haleon Corporate
